CPT code 30100 denotes an intranasal biopsy — removal of a tissue sample from within the nasal cavity for diagnostic evaluation. Nasal biopsies are a key diagnostic tool for evaluating suspicious lesions, chronic inflammatory conditions, and suspected neoplasms of the nasal cavity and adjacent structures. Nationally, accurate coding for this procedure affects diagnostic pathways, clinical documentation, and appropriate claims processing.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage considerations, common clinical contexts for use, and typical sites of service. The publication summarizes standard coding intent, common modifier usage (listed separately), and the procedural setting implications for ambulatory surgical centers, hospital outpatient departments, and office-based procedures.

The article provides practical benchmarks for how this diagnostic procedure is billed and categorized, highlights policy and documentation elements that influence reimbursement, and situates the code within clinical workflows for nasal pathology evaluation. Data not available in the input is noted where applicable.